Current hepatitis E treatments rely heavily on ribavirin, an antiviral with notable side effects that proves unsuitable for many patients. This gap has driven researchers to explore cellular machinery that viruses hijack for infection, potentially revealing more targeted therapeutic approaches. A comprehensive screening of compounds targeting endocytic pathways has identified apilimod, a PIKfyve kinase inhibitor, as a potent blocker of hepatitis E virus infection. The compound demonstrated superior antiviral activity compared to four other endocytic modulators, including established drugs like chloroquine and verapamil. PIKfyve regulates endolysosomal trafficking—the cellular highway that hepatitis E virus exploits to reach infection sites within host cells. When researchers knocked down PIKfyve expression using targeted siRNA, they confirmed the enzyme's essential role in viral replication. Time-of-addition experiments revealed apilimod's effectiveness during early infection stages, suggesting it disrupts viral entry rather than later replication steps. The compound's antiviral activity extended beyond cell culture models to primary human hepatocytes and an in vivo rat infection model, demonstrating broader therapeutic potential. This finding represents a mechanistically distinct approach to hepatitis E treatment, targeting host cell machinery rather than viral proteins directly. Such host-directed therapies often present higher barriers to viral resistance development since they don't directly pressure viral evolution. However, the clinical translation requires careful evaluation of PIKfyve inhibition's broader cellular effects, as this kinase regulates multiple cellular processes beyond viral trafficking. The research provides compelling preclinical evidence for repurposing existing PIKfyve inhibitors as hepatitis E therapeutics.